Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis

Jasvinder A Singh^{1

2

3}

Affiliations

¹ Birmingham Veterans Affairs (VA) Medical Center, Birmingham, Alabama.
² School of Medicine, Department of Medicine, University of Alabama at Birmingham.
³ School of Public Health, Division of Epidemiology, University of Alabama at Birmingham.

Editorial

Jasvinder A Singh. JAMA. 2019.

. 2019 Jul 23;322(4):309-311.

doi: 10.1001/jama.2019.9056.

Jasvinder A Singh^{1

2

3}

¹ Birmingham Veterans Affairs (VA) Medical Center, Birmingham, Alabama.
² School of Medicine, Department of Medicine, University of Alabama at Birmingham.
³ School of Public Health, Division of Epidemiology, University of Alabama at Birmingham.

No abstract available

Comment on

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy JS, de Vlam K, Walker D, Takeuchi T. Genovese MC, et al. JAMA. 2019 Jul 23;322(4):315-325. doi: 10.1001/jama.2019.9055. JAMA. 2019. PMID: 31334793 Free PMC article. Clinical Trial.